Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma— An exclamation sign with a question mark

OncoImmunology

Volumn 4, Issue 7, 2015, Pages 1-3

  Kroemer, Guido ^a,b,c,d,e,f   Galluzzi, Lorenzo ^a,b,c,d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

CTLA4; OpdivoTM; PD 1; PD L1; Pembrolizumab; Yervoy

Indexed keywords

IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; INTERLEUKIN 17; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DISEASE COURSE; DRUG EFFICACY; HUMAN; METASTATIC MELANOMA; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

EID: 84944449557     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1058037     Document Type: Article

References (36)

1. Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L,KroemerG,Galluzzi L. Trial watch: Immunostimulatory cytokines in cancer therapy. OncoImmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
2. Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory cytokines. OncoImmunology 2013; 2: e24850; PMID:24073369; http://dx.doi.org/10.4161/ onci.24850
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
4. Mavilio D, Lugli E. Inhibiting the inhibitors: Checkpoints blockade in solid tumors. OncoImmunology 2013; 2:e26535; PMID:24244910; http://dx.doi.org/ 10.4161/onci.26535
5. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. OncoImmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
6. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7; PMID:22614989; http://dx.doi.org/10.1200/JCO. 2012.41.6750
7. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8:e53745; PMID:23341990; http:// dx.doi.org/10.1371/journal.pone.0053745
8. Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. OncoImmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/ 10.4161/onci.22789
9. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16:522-30; PMID:25840693; http://dx.doi.org/ 10.1016/S1470-2045(15)70122-1
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/ NEJMoa1200690
11. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi. org/10.1056/NEJMoa1200694
12. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi. org/10.1200/JCO.2013.53.0105
13. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; http://dx.doi. org10.1056/NEJMoa1503093
14. Galluzzi L, Kroemer G, Eggermont A. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. OncoImmunology 2014; 3: e967147; PMID:25941597; http://dx.doi.org/ 10.4161/21624011.2014.967147
15. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-84; PMID:25795410; http://dx. doi.org/10.1016/S1470-2045(15)70076-8
16. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; http://dx.doi.org/10.1016/ S0140-6736(14)60958-2
17. Riley JL. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med 2013; 369:187-9; PMID:23724866; http://dx. doi.org/10.1056/NEJMe1305484
18. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa 1302369
19. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428
20. Hodi FS, Postow MA, Chesney JA, Pavlick AC, Robert C, Grossmann KF, et al. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. ASCO Meeting Abstracts 2015; 33:9004
21. Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). ASCO Meeting Abstracts 2014; 32:LBA9003
22. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). ASCO Meeting Abstracts 2015; 33:LBA1
23. Liu X, Gibbons RM, Harrington SM, Krco CJ, Markovic SN, Kwon ED, Dong H. Endogenous tumorreactive CD8 T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. OncoImmunology 2013; 2:e23972; PMID:23894697; http://dx.doi.org/ 10.4161/onci.23972
24. Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. OncoImmunology 2014; 3:e29244; PMID:25083336; http://dx.doi.org/ 10.4161/onci.29244
25. Hannani D, Vetizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015; 25:208-24; PMID:25582080; http://dx.doi.org/10.1038/cr.2015.3
26. Taube JM. Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. OncoImmunology 2014; 3:e963413; PMID:25914862; http://dx.doi.org/10.4161/21624011.2014.963413
27. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; PMID:25537519
28. Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. OncoImmunology 2013; 2:e25396; PMID:23894726; http:// dx.doi.org/10.4161/onci.25396
29. Cooper ZA, Reuben A, Amaria RN, Wargo JA. Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. OncoImmunology 2014; 3:e954956; PMID:25941608; http://dx.doi.org/10.4161/21624011. 2014.954956
30. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc 1302338
31. Nagato T, Celis E. A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/ PD-L1 pathway. OncoImmunology 2014; 3:e28440; PMID:25050210; http://dx.doi.org/10.4161/onci. 28440
32. Young A, Mittal D, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ, et al. Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. OncoImmunology 2014; 3: e958952; PMID:25941583; http://dx.doi.org/ 10.4161/21624011.2014.958952
33. Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Herve Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G, et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. OncoImmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/ 10.4161/onci.28344
34. Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L, et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. OncoImmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/onci. 24238
35. Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Herve Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: DNA vaccines for cancer therapy. OncoImmunology 2014; 3:e28185; PMID:24800178; http://dx.doi.org/10.4161/onci.28185
36. Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L, et al. Trial Watch: Peptide vaccines in cancer therapy. OncoImmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621